BPC-157 + TB-500: Full Specification, Mechanism and Dosing

This is not a single molecule. It is two separate synthetic peptides, each with its own research literature, dissolved together so one draw delivers a fixed amount of both. Everything here about mechanism and evidence is about the components individually.

BPC-157 is a pentadecapeptide — fifteen amino acids, sequence GEPPPGKPADDAGLV — and a partial sequence of a larger protein called Body Protection Compound, isolated from human gastric juice. It was first investigated for the digestive tract; the tendon and soft-tissue work came later.

TB-500 is related to thymosin beta-4, a 43-amino-acid protein among the most abundant inside human cells, whose central function is binding actin. As the FDA's own review describes it, TB-500 is understood today to be a synthetic seven-amino-acid fragment of thymosin beta-4 — residues 17 to 23, the actin-binding region, with an acetyl group on the first amino acid — not the full-length protein. Most of the published work, and all of the human work, used the full-length protein.

It is not a hormone or a steroid: neither component binds an androgen receptor, suppresses your own hormone production, or adds muscle directly. It is not a painkiller; nothing in either literature describes an analgesic mechanism. And it is not a treatment for a structural problem — a complete rupture, a displaced fracture or a torn meniscus is a surgical question.

The most frequently described BPC-157 mechanism is angiogenesis — new blood vessels growing into tissue. A 2017 paper in the Journal of Molecular Medicine reported BPC-157 activating the VEGFR2 receptor and the downstream Akt–eNOS pathway in cell and rodent models; rat work in the Journal of Physiology and Pharmacology in 2009 described it modulating angiogenesis in muscle and tendon healing, and several papers describe an interaction with the nitric oxide system. Injured tendon and ligament are poorly vascularised, and blood supply is often what limits recovery.

A 2014 paper in Molecules reported BPC-157 increasing growth hormone receptor expression in cultured rat tendon fibroblasts — not raising growth hormone levels, but making those cells more responsive to what is already circulating. A companion 2011 paper in the same journal described BPC-157 promoting tendon fibroblast outgrowth, survival and migration through focal adhesion kinase and paxillin, the proteins that govern how cells attach and move into a wound.

Thymosin beta-4's central described function is binding monomeric actin, the protein that gives a cell its structure and lets it move. A 2005 review in Trends in Molecular Medicine describes how this actin-sequestering protein "moonlights" in tissue repair: cells migrating into a wound reorganise their actin, and thymosin beta-4 is described as central to that. Work on the full-length protein also reports new vessel growth, downregulation of inflammatory mediators, and less scar in some injury models.

The animal studies, reviews and human trials below used full-length thymosin beta-4. TB-500 is the fragment containing the actin-binding motif, and the working assumption in prescribing has been that it carries the relevant activity. The FDA's July 2026 review found cell work in which the fragment showed wound-closure activity in some assays and not others, and no animal or human wound-healing studies of the fragment itself. So: mechanism described in detail for the parent protein, inferred for the fragment.

Healing runs in overlapping phases: inflammation, cell migration, new vessel growth, collagen synthesis and remodelling. BPC-157's literature sits mainly on the vascular side and tendon-cell signalling; thymosin beta-4's on cell motility and limiting scar. Blood supply without cells is a dead end, and cells without blood supply is the same. Clinicians combine them because the described mechanisms are complementary, and one vial means one injection, one schedule and one refill.

That is a coherent mechanistic argument, not a trial result: no published study has tested the pair against either component alone.

The strongest BPC-157 area. A 2003 paper in the Journal of Orthopaedic Research reported accelerated healing of transected Achilles tendon in rats along with stimulation of tendon cell growth in vitro; a 2006 paper in the same journal reported improved reattachment and functional recovery after Achilles detachment from bone. With the cell work above, it is a consistent rodent story: better blood supply, more responsive cells, faster migration into the gap.

Rat models of transected quadriceps and crush injury, in the Journal of Orthopaedic Research in 2006 and Surgery Today in 2008, report faster functional recovery measured as limb function and force.

The deepest BPC-157 literature, and where the compound was first identified. Animal work describes protection of the gut lining against NSAID- and alcohol-induced damage and improvement in inflammatory bowel models; reviews in Current Pharmaceutical Design in 2011 and 2018 cover it, arguing the vascular effects in tendon and muscle are the same mechanism at work in the gut.

The largest thymosin beta-4 literature. A 1999 paper in the Journal of Investigative Dermatology reported topical and injected thymosin beta-4 accelerating closure of full-thickness wounds in rats, with more collagen and more cells migrating in; a 2010 review in the Annals of the New York Academy of Sciences summarises the animal work across skin, cornea and other tissues, and a 2004 paper in Nature reported it promoting cardiac cell migration and survival in mice after coronary ligation. Those are where the mechanism is best characterised, not indications for this vial, and all of it is full-length thymosin beta-4.

There are no published studies — animal, cell or human — of BPC-157 and TB-500 given together. Anything describing "studies on the stack" is describing studies of one component or the other.

This is the honest part, and worth reading before starting.

For BPC-157, there are no large randomised controlled trials in humans. The FDA's July 2026 review identified one small randomised, placebo-controlled study of a BPC-157 enema in 53 people with ulcerative colitis, reported only as a 2005 meeting abstract, in which the difference between groups was not statistically distinguishable. There are no published human trials of BPC-157 by injection for tendon, ligament or muscle injury.

For thymosin beta-4 — the full-length protein — human trials exist, but not for the TB-500 fragment. A randomised, placebo-controlled dose study of intravenous thymosin beta-4 in healthy volunteers (Annals of the New York Academy of Sciences, 2010) reported it well tolerated. Phase 2 trials of a topical thymosin beta-4 gel in pressure ulcers, venous stasis ulcers and epidermolysis bullosa (same journal, 2012) reported faster closure in some dose groups than placebo. A phase 2 randomised trial of thymosin beta-4 eye drops in severe dry eye (Cornea, 2015) reported improvement in signs and symptoms. None used TB-500, subcutaneous injection, or a tendon or muscle population.

For the combination, there are no human trials of any size. The honest framing is "described in preclinical research for each component and used clinically together," not "proven in people."

• It does not establish an effect size for the combination, or either component, in human injury.
• It does not establish that the combination outperforms either peptide alone. That comparison has never been made.
• It does not establish that the TB-500 fragment behaves like full-length thymosin beta-4 in people; that is an inference from the shared sequence.
• It does not establish a timeline in humans. Prescriber timelines are clinical experience, not trial endpoints.
• It does not establish long-term safety over years of continuous use.
• It does not establish efficacy for any condition as an FDA-approved treatment. Neither component is approved for anything.

Mostly background inflammation settling rather than the injury changing, and often nothing beyond injection-site tenderness. That is normal.

Prescribers commonly describe reduced background ache and a problem area less reactive after activity.

Where tissue-level change would be expected if it occurs, based on the animal timelines. What prescribers describe is better tolerance to loading, which is where rehabilitation progress shows. The second vial covers this window.

Chronic problems — a tendon sore for a year — are generally described as needing longer than a recent acute injury. Around eight weeks is a natural point to review with your physician whether it is earning its place. No withdrawal or rebound is described in either literature.

The directions are written in millilitres and insulin-syringe units because that is what you read off the barrel. 0.25 mL is 25 units on a U-100 syringe, printed on your medication. At that volume the 5 mg / 5 mg vial delivers 0.25 mg of each peptide per injection, and the 10 mg / 10 mg vial 0.5 mg of each.

The reviewed schedule is Monday through Friday, mornings. Five days on, two off is a common convention for recovery peptides: easy to keep to, and it maps the vial's 20 doses onto four working weeks. Nothing shows daily dosing is required. Your own directions are what count.

Into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated. Some prescribers direct injection near the affected area; others do not, because the mechanisms described are systemic. Your directions will say.

20 doses at one per weekday is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way with ice packs. Beyond-use dating runs from first puncture and is on the label.

BPC-157 alone is the choice when the complaint is digestive, or when you and your physician want a single agent to judge on its own. TB-500 alone is rarely prescribed in practice. The combination is the usual choice for tendon, ligament, muscle and post-surgical recovery, where prescribers want both mechanisms at once.

KLOW adds GHK-Cu and KPV to the same two peptides; GLOW adds GHK-Cu. The additions are aimed at skin, collagen and inflammation. If the goal is injury recovery and nothing else, the two-peptide vial is the simpler prescription with fewer variables.

Identical medication. The pepti Pen is a pre-filled 3 mL cartridge containing 9 mg BPC-157 and 13.5 mg TB-500 in a reusable click-dial injector, dosed in clicks. Its ratio of the two peptides differs from the vial's, so Pen directions are written separately. It costs more and removes the draw step. Neither is clinically better.